Updated Diabetes Treatment Guidelines Prioritizes Clinical Cardiovascular Disease

By March 31, 2016Blog Posts, Pharma Beat

The Canadian Diabetes Association (CDA) has provided an interim update to their clinical practice guidelines for the pharmacologic management of type 2 diabetes. The guidelines initially published in 2013, are set to be fully updated in 2018, and contain a provision allowing individual chapters to be updated in the event of significant changes in supporting evidence.

This update follows the results of a recent cardiovascular outcome studies (EMPAREG OUTCOME) for the sodium glucose transporter 2 (SGLT2) inhibitor, empagliflozin. This is the first trial to demonstrate cardiovascular superiority with antihyperglycemic treatment. In this trial significantly fewer patients receiving empagliflozin died from cardiovascular causes or experienced a nonfatal myocardial infarction or nonfatal stroke when compared to placebo.
These findings are significant to the diabetic population as 40% to 60% of individuals with diabetes will die from cardiovascular disease. As a result, the CDA now prioritizes the presence of clinical cardiovascular disease when adding an antihyperglycemic and recommends an SGLT2 inhibitor with demonstrated CV benefits in this patient population.